RxDoctor Payments Data

Stephen Montgomery, MD

Family Medicine · Pontotoc, MSNPI 1699735159

Payments from drug & device makers

$1,841in general payments, 2019–2025

Across 116 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$343
  • Otsuka America Pharmaceutical, Inc.$229
  • Novo Nordisk$163
  • Pfizer$160
  • AstraZeneca$128
  • Johnson & Johnson$125
  • plus $693 from 16 others

What the payments were for

  • Food & beverage$1,841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,841 in reported general payments places this provider in the 65th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,771
Medicare patients
45
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$168,227
JardianceEmpagliflozin142$81,711
FarxigaDapagliflozin Propanediol147$69,182
TivicayDolutegravir Sodium24$53,854
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$42,447
XareltoRivaroxaban67$36,653
LinzessLinaclotide71$28,578
OzempicSemaglutide27$24,567
TradjentaLinagliptin38$22,019
MyrbetriqMirabegron49$19,769
TrulicityDulaglutide20$18,991
GlyxambiEmpagliflozin/Linagliptin22$16,369
EntrestoSacubitril/Valsartan30$15,916
MounjaroTirzepatide14$14,689
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$168,227368 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$20$120,099202 claims
AstraZenecaFarxiga$128$69,182147 claims
AbbVieLinzess, Restasis, Synthroid$117$44,136179 claims
Johnson & JohnsonXarelto$125$36,65367 claims
Lilly USA, LLCTrulicity, Mounjaro$91$33,67934 claims
Novo NordiskOzempic$163$24,56727 claims
Astellas Pharma US IncMyrbetriq$22$19,76949 claims
NovartisEntresto$14$15,91630 claims
GSKAnoro Ellipta$41$11,18823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Pontotoc

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →